Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Activity limited with trebananib plus sorafenib in hepatocellular carcinoma

Jan. 22, 2014

Phase II data show limited single-agent activity with ganetespib in metastatic pancreatic cancer

Jan. 22, 2014

New radioligands tested for assessment of AD in living subjects

Jan. 21, 2014

Preliminary trial results provided for selinexor in colorectal cancer

Jan. 21, 2014

Nektar Therapeutics reviews product development status for 2014

Jan. 21, 2014

Simtuzumab well tolerated in phase I and II trials

Jan. 21, 2014

Lanreotide autogel/depot reduces carcinoid syndrome rescue therapy in ELECT trial

Jan. 21, 2014

Safety issues noted in phase I study of cabazitaxel in gastric adenocarcinoma

Jan. 21, 2014

Karyopharm targets PAK-4 in pancreatic cancer

Jan. 20, 2014

Development of a novel class of tau ligands for medical imaging of AD

Jan. 20, 2014

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.